Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real‐world data analysis

BACKGROUND & AIMS: There is intense research for drugs able to reduce disease progression in nonalcoholic fatty liver disease. We aimed to test the impact of novel antidiabetic drugs (dipeptidyl‐peptidase‐4 inhibitors – DPP‐4Is, glucagon‐like peptide‐1 receptor agonists – GLP‐1RAs, sodium‐glucos...

Descripción completa

Detalles Bibliográficos
Autores principales: Colosimo, Santo, Ravaioli, Federico, Petroni, Maria L., Brodosi, Lucia, Marchignoli, Francesca, Barbanti, Francesca A., Sasdelli, Anna S., Marchesini, Giulio, Pironi, Loris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Metabolic & Toxic Liver Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248247/
https://www.ncbi.nlm.nih.gov/pubmed/33497019
http://dx.doi.org/10.1111/liv.14799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248247/
https://www.ncbi.nlm.nih.gov/pubmed/33497019
http://dx.doi.org/10.1111/liv.14799

Ejemplares similares